US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6281015B1
(en)
|
1994-12-16 |
2001-08-28 |
Children's Medical Center Corp. |
Localized delivery of factors enhancing survival of transplanted cells
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
US5780462A
(en)
*
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
GB9606452D0
(en)
|
1996-03-27 |
1996-06-05 |
Sandoz Ltd |
Organic compounds
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
US8790391B2
(en)
|
1997-04-18 |
2014-07-29 |
Cordis Corporation |
Methods and devices for delivering therapeutic agents to target vessels
|
US6273913B1
(en)
*
|
1997-04-18 |
2001-08-14 |
Cordis Corporation |
Modified stent useful for delivery of drugs along stent strut
|
US6984635B1
(en)
*
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
TWI256395B
(en)
*
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
US8236048B2
(en)
|
2000-05-12 |
2012-08-07 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US6670355B2
(en)
*
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
DE60106281T2
(de)
|
2000-08-11 |
2005-02-24 |
Wyeth |
Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
|
CA2421485A1
(fr)
|
2000-09-19 |
2002-03-28 |
Wyeth |
Esters de rapamycine hydrosolubles
|
US6399625B1
(en)
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
US20070276473A1
(en)
*
|
2000-09-29 |
2007-11-29 |
Llanos Gerard H |
Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon
|
US20060222756A1
(en)
*
|
2000-09-29 |
2006-10-05 |
Cordis Corporation |
Medical devices, drug coatings and methods of maintaining the drug coatings thereon
|
ES2275737T3
(es)
|
2000-09-29 |
2007-06-16 |
Cordis Corporation |
Dispositivos medicos revestidos.
|
US6399626B1
(en)
*
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
NZ526708A
(en)
|
2000-11-28 |
2005-07-29 |
Wyeth Corp |
Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
EP1363627A2
(fr)
|
2001-02-19 |
2003-11-26 |
Novartis AG |
Traitement des cancers
|
TWI233359B
(en)
*
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
TWI296196B
(en)
*
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
HUP0304093A3
(en)
*
|
2001-04-06 |
2008-08-28 |
Wyeth Corp |
Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them
|
ZA200603888B
(en)
*
|
2001-06-01 |
2007-05-30 |
Wyeth Corp |
Antineoplastic combinations
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
ES2246409T3
(es)
|
2001-08-22 |
2006-02-16 |
Wyeth |
29-enoles de rapamicina.
|
CA2455311A1
(fr)
*
|
2001-08-22 |
2003-03-06 |
Wyeth |
Dialdehydes rapamycine
|
US6939376B2
(en)
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US7682387B2
(en)
*
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
PL216224B1
(pl)
|
2002-02-01 |
2014-03-31 |
Ariad Pharmaceuticals |
Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
DK1505959T3
(da)
|
2002-05-16 |
2009-02-23 |
Novartis Ag |
Anvendelse af EDG-receptorbindingsmidler ved cancer
|
IL165256A0
(en)
*
|
2002-05-24 |
2005-12-18 |
Schering Corp |
Neutralizing human anti-igfr antibody
|
AU2003240714B2
(en)
|
2002-05-27 |
2006-09-28 |
Irm Llc |
Bis-aromatic alkanols
|
WO2003106622A2
(fr)
*
|
2002-05-30 |
2003-12-24 |
The Children's Hospital Of Philadelphia |
Procedes de traitement de la leucemie lymphoide aigue
|
EP1655372A3
(fr)
|
2002-07-16 |
2008-01-16 |
Biotica Technology Limited |
Production des polyketides et d'autres produits naturels
|
CN100402031C
(zh)
|
2002-07-30 |
2008-07-16 |
惠氏公司 |
含有瑞帕霉素羟基酯的胃肠外制剂
|
RU2005106855A
(ru)
*
|
2002-08-12 |
2005-10-10 |
Дзе Риджентс оф дзе Юниверсити оф Мичиган (US) |
Диагностика и лечение заболеваний, вызываемых дефектами каскада реакций, обусловливающих туберозный склероз
|
AU2003272489B2
(en)
*
|
2002-09-17 |
2008-11-13 |
Wyeth |
Granulated formulation of the rapamycin ester CCI779
|
US20070078513A1
(en)
*
|
2002-09-18 |
2007-04-05 |
Medtronic Vascular, Inc. |
Controllable drug releasing gradient coatings for medical devices
|
US20060046979A1
(en)
|
2002-09-24 |
2006-03-02 |
Foster Carolyn A |
Organic compounds
|
AU2003293529A1
(en)
|
2002-12-16 |
2004-07-29 |
Nitromed, Inc. |
Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
|
ES2395082T3
(es)
*
|
2003-01-27 |
2013-02-08 |
Endocyte, Inc. |
Conjugado de folato-vinblastina como medicamento
|
AR042938A1
(es)
*
|
2003-02-06 |
2005-07-06 |
Wyeth Corp |
Uso del cci-779 en el tratamiento de la fibrosis hepatica
|
UA83484C2
(uk)
*
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
US20040258662A1
(en)
*
|
2003-04-22 |
2004-12-23 |
Wyeth |
Antineoplastic agents
|
CA2522980A1
(fr)
*
|
2003-04-23 |
2004-11-04 |
Wyeth Holdings Corporation |
Derives de wortmannine solubles dans l'eau
|
US7160867B2
(en)
*
|
2003-05-16 |
2007-01-09 |
Isotechnika, Inc. |
Rapamycin carbohydrate derivatives
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
BRPI0410439A
(pt)
|
2003-05-19 |
2006-06-06 |
Irm Llc |
compostos e composições imunossupressoras
|
TW200500065A
(en)
*
|
2003-05-21 |
2005-01-01 |
Wyeth Corp |
Antiarthritic combinations
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
EP1636360A4
(fr)
*
|
2003-06-03 |
2006-11-08 |
Cell Genesys Inc |
Compositions et methodes pour une expression amelioree de polypeptides recombinants a partir d'un vecteur unique, faisant appel a un site de clivage peptidique
|
BRPI0412659A
(pt)
*
|
2003-07-16 |
2006-09-26 |
Wyeth Corp |
isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
|
EP1648454A1
(fr)
*
|
2003-07-25 |
2006-04-26 |
Wyeth |
Formulations de cci-779 lyophilise
|
WO2005016935A2
(fr)
*
|
2003-08-07 |
2005-02-24 |
Wyeth |
Synthese stereoselective de cci-779
|
JP2007504226A
(ja)
*
|
2003-09-03 |
2007-03-01 |
ワイス |
非晶質状のラパマイシンの3−ヒドロキシ−2−(ヒドロキシメチル)−2−メチルプロピオン酸との42−エステル、およびそれを含むその医薬組成物
|
AR046194A1
(es)
|
2003-11-04 |
2005-11-30 |
Mayo Foundation |
Metodo de tratamiento del linfoma de celulas del manto
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
AR046639A1
(es)
*
|
2003-11-21 |
2005-12-14 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti- igfr1
|
UA84903C2
(ru)
*
|
2004-01-08 |
2008-12-10 |
Уайет |
Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием
|
AR047988A1
(es)
*
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
JP2007530654A
(ja)
*
|
2004-03-30 |
2007-11-01 |
ファイザー・プロダクツ・インク |
シグナル伝達阻害剤の組合せ
|
MXPA06011881A
(es)
*
|
2004-04-14 |
2006-12-14 |
Wyeth Corp |
Sintesis regioespecifica de derivados de ester-42 de rapamicina.
|
PL1735321T3
(pl)
*
|
2004-04-14 |
2009-04-30 |
Wyeth Corp |
Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała
|
WO2005100366A1
(fr)
|
2004-04-14 |
2005-10-27 |
Wyeth |
Proline cci-779 (ester de proline-rapamycine 42 avec acide propionique de 2,2-bis (hydroxymethyle) et synthese enzymatique en deux etapes de proline cci-779 et cci-779 par lipase microbienne
|
US20050239178A1
(en)
*
|
2004-04-27 |
2005-10-27 |
Wyeth |
Labeling of rapamycin using rapamycin-specific methylases
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
WO2006017325A2
(fr)
*
|
2004-07-13 |
2006-02-16 |
Cell Genesys, Inc. |
Compositions de vecteurs aav et procédés pour l'expression accrue d'immunoglobulines utilisant celles-ci
|
EP1789391B1
(fr)
|
2004-07-23 |
2017-06-28 |
Endocyte, Inc. |
Groupes de liaison bivalents et conjugués de ceux-ci
|
PE20060642A1
(es)
*
|
2004-08-10 |
2006-08-01 |
Wyeth Corp |
Derivados de 42-ester de rapamicina con acido 2,2-bis(hidoximetil)propionico (cci-779) y metodos para su preparacion
|
GB0417852D0
(en)
|
2004-08-11 |
2004-09-15 |
Biotica Tech Ltd |
Production of polyketides and other natural products
|
US7901451B2
(en)
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
EP1804751A2
(fr)
*
|
2004-10-04 |
2007-07-11 |
QLT USA, Inc. |
Apport oculaire de preparations d'apport polymere
|
US8313763B2
(en)
*
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
CN101048152A
(zh)
*
|
2004-10-28 |
2007-10-03 |
惠氏公司 |
mTOR抑制剂在治疗子宫平滑肌瘤中的应用
|
US20080221660A1
(en)
*
|
2004-10-28 |
2008-09-11 |
Medtronic Vascular, Inc. |
Platelet Gel for Treatment of Aneurysms
|
US8021849B2
(en)
*
|
2004-11-05 |
2011-09-20 |
Siemens Healthcare Diagnostics Inc. |
Methods and kits for the determination of sirolimus in a sample
|
RU2405566C2
(ru)
|
2005-02-03 |
2010-12-10 |
Дзе Дженерал Хоспитал Корпорейшн |
Способ лечения рака, устойчивого к гефитинибу
|
CN101115759A
(zh)
*
|
2005-02-09 |
2008-01-30 |
惠氏公司 |
Cci-779多晶形物及其应用
|
JP2008530145A
(ja)
*
|
2005-02-15 |
2008-08-07 |
ワイス |
経口投与可能なcci−779製剤
|
GB0503936D0
(en)
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
AU2006218918A1
(en)
*
|
2005-03-02 |
2006-09-08 |
Wyeth |
Purification of rapamycin
|
KR20070107072A
(ko)
*
|
2005-03-02 |
2007-11-06 |
와이어쓰 |
모액으로부터의 cci-779의 회수
|
GB0504544D0
(en)
|
2005-03-04 |
2005-04-13 |
Novartis Ag |
Organic compounds
|
KR20070116868A
(ko)
|
2005-03-11 |
2007-12-11 |
바이오티카 테크놀로지 리미티드 |
39데스메톡시라파마이신 및 그 유사체의 의학적 용도
|
US20100061994A1
(en)
*
|
2005-03-11 |
2010-03-11 |
Rose Mary Sheridan |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
GB0504994D0
(en)
*
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
EP1863816B1
(fr)
*
|
2005-03-16 |
2014-06-25 |
Endocyte, Inc. |
Synthese et purification d'acide pteroique et des conjugues de celui-ci
|
MX2007012896A
(es)
*
|
2005-04-15 |
2007-12-10 |
Schering Corp |
Metodos y composiciones para tratamiento o prevencion de cancer.
|
US7189582B2
(en)
*
|
2005-04-27 |
2007-03-13 |
Dade Behring Inc. |
Compositions and methods for detection of sirolimus
|
US20070004767A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Gutmann David H |
Methods for treating neurofibromatosis 1
|
US20090062909A1
(en)
|
2005-07-15 |
2009-03-05 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
ES2691646T3
(es)
|
2005-07-15 |
2018-11-28 |
Micell Technologies, Inc. |
Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
|
US7632509B2
(en)
*
|
2005-07-19 |
2009-12-15 |
Biosante Pharmaceuticals, Inc. |
Methods to express recombinant proteins from lentiviral vectors
|
WO2007014278A2
(fr)
|
2005-07-25 |
2007-02-01 |
Trubion Pharmaceuticals, Inc. |
Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
|
KR101364912B1
(ko)
|
2005-08-19 |
2014-02-21 |
엔도사이트, 인코포레이티드 |
복수-약제 리간드 공액체
|
US8021679B2
(en)
|
2005-08-25 |
2011-09-20 |
Medtronic Vascular, Inc |
Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
|
AU2006284922B2
(en)
|
2005-08-30 |
2012-01-19 |
University Of Miami |
Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
|
WO2007056175A2
(fr)
*
|
2005-11-04 |
2007-05-18 |
Wyeth |
42-ester de rapamycine marque par isotope par un 41-methoxy
|
PE20070763A1
(es)
|
2005-11-04 |
2007-08-08 |
Wyeth Corp |
COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
|
KR20080077619A
(ko)
*
|
2005-12-07 |
2008-08-25 |
와이어쓰 |
라파마이신 42-에스테르 보로네이트로부터 라파마이신42-에스테르를 제조하는 가변적인 방법
|
AR058283A1
(es)
*
|
2005-12-07 |
2008-01-30 |
Wyeth Corp |
Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
|
BRPI0619493A2
(pt)
*
|
2005-12-07 |
2016-09-06 |
Wyeth Corp |
forma cristalina purificada de cci-779, processo para a purificação de cc-779, produto, método para monitorar a cristalização de cci-779, kit, composição farmacêutica, método para o tratamento de câncer, e, uso de um cci-779 purificado
|
RU2473343C2
(ru)
*
|
2006-02-02 |
2013-01-27 |
Новартис Аг |
Лечение туберозного склероза
|
US20070203169A1
(en)
*
|
2006-02-28 |
2007-08-30 |
Zhao Jonathon Z |
Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
|
KR20080106225A
(ko)
*
|
2006-03-07 |
2008-12-04 |
와이어쓰 |
마크롤라이드 면역억제제의 수용성 폴리에틸렌 글리콜 콘쥬게이트를 제조하는 방법
|
DE102006011507A1
(de)
*
|
2006-03-14 |
2007-09-20 |
Lts Lohmann Therapie-Systeme Ag |
Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
|
US20070292922A1
(en)
*
|
2006-03-31 |
2007-12-20 |
Cell Genesys, Inc. |
Regulated expression of recombinant proteins from adeno-associated viral vectors
|
ES2540059T3
(es)
|
2006-04-26 |
2015-07-08 |
Micell Technologies, Inc. |
Recubrimientos que contienen múltiples fármacos
|
US8241619B2
(en)
|
2006-05-15 |
2012-08-14 |
Medtronic Vascular, Inc. |
Hindered amine nitric oxide donating polymers for coating medical devices
|
GB0609962D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
GB0609963D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
EP2040758A4
(fr)
*
|
2006-06-30 |
2014-09-17 |
Interface Biologics Inc |
Polymeres biosensibles
|
US20080207671A1
(en)
*
|
2006-07-31 |
2008-08-28 |
The Regents Of The University Of Michigan |
Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
|
WO2008016633A2
(fr)
*
|
2006-08-02 |
2008-02-07 |
Ariad Gene Therapeutics, Inc. |
Thérapie par combinaison
|
WO2008022256A2
(fr)
*
|
2006-08-16 |
2008-02-21 |
Blagosklonny Mikhail V |
Procédés et compositions de prévention ou de traitement de maladies liées au vieillissement
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
CN104906087A
(zh)
|
2006-09-13 |
2015-09-16 |
万能医药公司 |
大环内酯化合物及它们的使用方法
|
TW200824713A
(en)
*
|
2006-10-18 |
2008-06-16 |
Wyeth Corp |
Processes for the synthesis of individual isomers of mono-PEG CCI-779
|
US20080097591A1
(en)
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
US8067055B2
(en)
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
US7691402B2
(en)
*
|
2006-11-06 |
2010-04-06 |
Medtronic Vascular, Inc. |
Block biodegradable copolymers for medical devices
|
US20080242648A1
(en)
*
|
2006-11-10 |
2008-10-02 |
Syndax Pharmaceuticals, Inc., A California Corporation |
COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8430055B2
(en)
|
2008-08-29 |
2013-04-30 |
Lutonix, Inc. |
Methods and apparatuses for coating balloon catheters
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8414909B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
EP2090580B1
(fr)
*
|
2006-11-27 |
2014-06-04 |
Terumo Kabushiki Kaisha |
Procédé de fabrication d'un dérivé de rapamycine o-alkylé, et dérivé de rapamycine o-alkylée
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
JP5603598B2
(ja)
|
2007-01-08 |
2014-10-08 |
ミセル テクノロジーズ、インコーポレイテッド |
生物分解層を有するステント
|
US7753962B2
(en)
*
|
2007-01-30 |
2010-07-13 |
Medtronic Vascular, Inc. |
Textured medical devices
|
US20080188461A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Regents Of The University Of Michigan |
Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
|
US20100104626A1
(en)
|
2007-02-16 |
2010-04-29 |
Endocyte, Inc. |
Methods and compositions for treating and diagnosing kidney disease
|
US7811600B2
(en)
*
|
2007-03-08 |
2010-10-12 |
Medtronic Vascular, Inc. |
Nitric oxide donating medical devices and methods of making same
|
US7815927B2
(en)
*
|
2007-03-08 |
2010-10-19 |
Medtronic Vascular, Inc. |
Terpolymers for controlled release of bioactive agents from implantable medical devices
|
NZ580132A
(en)
|
2007-03-14 |
2012-11-30 |
Endocyte Inc |
Binding ligand linked drug delivery conjugates of tubulysins to vitamins
|
US20080245375A1
(en)
*
|
2007-04-05 |
2008-10-09 |
Medtronic Vascular, Inc. |
Benign Prostatic Hyperplasia Treatments
|
TW200845960A
(en)
*
|
2007-04-05 |
2008-12-01 |
Wyeth Corp |
Wortmannin-rapalog conjugate and uses thereof
|
TW200901989A
(en)
*
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
US20080306581A1
(en)
*
|
2007-06-07 |
2008-12-11 |
Medtronic Vascular, Inc. |
Streamlined Stents
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
EP2176293B1
(fr)
|
2007-06-25 |
2019-04-03 |
Endocyte, Inc. |
Conjugués contenant des lieurs espaceurs hydrophiles
|
US8852620B2
(en)
*
|
2007-07-20 |
2014-10-07 |
Medtronic Vascular, Inc. |
Medical devices comprising polymeric drug delivery systems with drug solubility gradients
|
US8273828B2
(en)
*
|
2007-07-24 |
2012-09-25 |
Medtronic Vascular, Inc. |
Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
|
US20090043378A1
(en)
*
|
2007-08-10 |
2009-02-12 |
Medtronic Vascular, Inc. |
Biocompatible Polymer System for Extended Drug Release
|
US20090076060A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched temsirolimus
|
KR100930167B1
(ko)
*
|
2007-09-19 |
2009-12-07 |
삼성전기주식회사 |
초광각 광학계
|
CA2701186C
(fr)
|
2007-10-05 |
2017-09-19 |
Interface Biologics Inc. |
Polymeres reticules oligofluores et leurs utilisations
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
ES2623456T3
(es)
|
2007-10-19 |
2017-07-11 |
Interface Biologics Inc. |
Recubrimientos autoeliminantes
|
US20090131367A1
(en)
*
|
2007-11-19 |
2009-05-21 |
The Regents Of The University Of Colorado |
Combinations of HDAC Inhibitors and Proteasome Inhibitors
|
WO2009089549A1
(fr)
*
|
2008-01-11 |
2009-07-16 |
Massachusetts Eye & Ear Infirmary |
Animaux transgéniques de caspase dimérisable d'arrêt conditionnel
|
US20090222088A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Medtronic Vascular, Inc. |
Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
|
US20100048913A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
US20090232863A1
(en)
*
|
2008-03-17 |
2009-09-17 |
Medtronic Vascular, Inc. |
Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
|
US20090232868A1
(en)
*
|
2008-03-17 |
2009-09-17 |
Medtronic Vascular, Inc. |
Nitric Oxide Releasing Polymer Composition
|
US20090240323A1
(en)
*
|
2008-03-20 |
2009-09-24 |
Medtronic Vascular, Inc. |
Controlled Degradation of Magnesium Stents
|
JP5647098B2
(ja)
|
2008-03-21 |
2014-12-24 |
ザ ユニヴァーシティー オヴ シカゴ |
オピオイド拮抗薬とmTOR阻害薬を用いた治療
|
US20090253733A1
(en)
*
|
2008-04-02 |
2009-10-08 |
Biointeractions, Ltd. |
Rapamycin carbonate esters
|
CN102099377A
(zh)
|
2008-04-11 |
2011-06-15 |
新兴产品开发西雅图有限公司 |
Cd37免疫治疗剂及其与双功能化学治疗剂的联合
|
US20110098241A1
(en)
*
|
2008-04-14 |
2011-04-28 |
Poniard Pharmaceuticals, Inc. |
Rapamycin analogs as anti-cancer agents
|
CA2721832C
(fr)
|
2008-04-17 |
2018-08-07 |
Micell Technologies, Inc. |
Stents a couches bioabsorbables
|
US20090269480A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Medtronic Vascular, Inc. |
Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
|
US20090297576A1
(en)
*
|
2008-06-02 |
2009-12-03 |
Medtronic Vascular, Inc. |
Local Delivery of PAR-1 Antagonists to Treat Vascular Complications
|
US20090299464A1
(en)
*
|
2008-06-02 |
2009-12-03 |
Medtronic Vascular, Inc. |
Reducing Bioabsorbtion Time of Polymer Coated Implantable Medical Devices Using Polymer Blends
|
MX365008B
(es)
|
2008-06-17 |
2019-05-20 |
Wyeth Llc |
Combinaciones antineoplasticas que contienen hki-272 y vinorelbina.
|
EP3545953A1
(fr)
|
2008-06-20 |
2019-10-02 |
Novartis AG |
Compositions pédiatriques pour le traitement de la sclérose en plaques
|
US9510856B2
(en)
|
2008-07-17 |
2016-12-06 |
Micell Technologies, Inc. |
Drug delivery medical device
|
AU2009270849B2
(en)
|
2008-07-17 |
2013-11-21 |
Micell Technologies, Inc. |
Drug delivery medical device
|
CN101676291B
(zh)
|
2008-09-18 |
2012-05-09 |
上海海和药物研究开发有限公司 |
一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
|
US20100086579A1
(en)
*
|
2008-10-03 |
2010-04-08 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
US20100092535A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Medtronic Vascular, Inc. |
Nanoporous Drug Delivery System
|
US20100092534A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Medtronic Vascular, Inc. |
Combination Local Delivery Using a Stent
|
DK2365802T3
(da)
|
2008-11-11 |
2017-11-13 |
Univ Texas |
Mikrokapsler af rapamycin og anvendelse til behandling af cancer
|
US20100131001A1
(en)
*
|
2008-11-24 |
2010-05-27 |
Medtronic Vascular, Inc. |
Targeted Drug Delivery for Aneurysm Treatment
|
US20100131051A1
(en)
*
|
2008-11-24 |
2010-05-27 |
Medtronic Vascular, Inc. |
Systems and Methods for Treatment of Aneurysms Using Zinc Chelator(s)
|
US20100152832A1
(en)
*
|
2008-12-12 |
2010-06-17 |
Medtronic Vascular, Inc. |
Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
|
DK2379497T3
(da)
|
2008-12-18 |
2013-11-25 |
Novartis Ag |
Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre
|
WO2010071794A1
(fr)
|
2008-12-18 |
2010-06-24 |
Novartis Ag |
Nouvelle forme polymorphe de 1-(4-{l-[(e)-4-cyclohexyl-3-trifluorométhyl-benzyloxyimino]-éthyl}-2-éthyl-benzyl)-azétidine-s-carboxylique
|
RU2011129229A
(ru)
|
2008-12-18 |
2013-01-27 |
Новартис Аг |
Новые соли
|
US8158187B2
(en)
*
|
2008-12-19 |
2012-04-17 |
Medtronic Vascular, Inc. |
Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
|
US20100198338A1
(en)
*
|
2009-01-30 |
2010-08-05 |
Medtronic Vascular, Inc., A Delaware Corporation |
Hydrogen Sulfide Donating Polymers
|
EP3023433A1
(fr)
|
2009-02-05 |
2016-05-25 |
Tokai Pharmaceuticals, Inc. |
Nouveaux promédicaments d'inhibiteurs cyp17/anti-androgènes stéroïdiens
|
US20100227799A1
(en)
*
|
2009-03-09 |
2010-09-09 |
Medtronic Vascular, Inc. |
Simultaneous photodynamic therapy and photo induced polymerization
|
CA2757276C
(fr)
|
2009-04-01 |
2017-06-06 |
Micell Technologies, Inc. |
Endoprotheses enduites
|
US8236341B2
(en)
*
|
2009-04-02 |
2012-08-07 |
Medtronic Vascular, Inc. |
Poly(tetrafluoroethylene) polymer with nitric oxide donating surface
|
US20100256728A1
(en)
*
|
2009-04-07 |
2010-10-07 |
Medtronic Vascular, Inc. |
Semi-Permiable Biodegradable Stent Graft and Uses Thereof
|
US8709465B2
(en)
*
|
2009-04-13 |
2014-04-29 |
Medtronic Vascular, Inc. |
Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
|
US8852590B2
(en)
|
2009-04-16 |
2014-10-07 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
WO2010121187A2
(fr)
|
2009-04-17 |
2010-10-21 |
Micell Techologies, Inc. |
Endoprothèses vasculaires ayant une élution contrôlée
|
US8716307B2
(en)
|
2009-05-13 |
2014-05-06 |
The Trustees Of The University Of Pennsylvania |
Combination antineoplastic therapy
|
ES2586837T3
(es)
|
2009-08-03 |
2016-10-19 |
University Of Miami |
Método para la expansión in vivo de linfocitos T reguladores
|
EP2480557A2
(fr)
|
2009-09-25 |
2012-08-01 |
Cadila Healthcare Limited |
Procédé de préparation de dérivés de rapamycine
|
EP2491032B1
(fr)
|
2009-10-23 |
2014-04-16 |
Eli Lilly and Company |
Inhibiteurs d'akt
|
EP2493460A4
(fr)
|
2009-10-30 |
2013-04-24 |
Ariad Pharma Inc |
Procédés et compositions pour le traitement du cancer
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
US20170079962A1
(en)
|
2009-11-11 |
2017-03-23 |
Rapamycin Holdings, Llc |
Oral Rapamycin Preparation and Use for Stomatitus
|
CN102933658A
(zh)
|
2009-12-18 |
2013-02-13 |
界面生物公司 |
从自组装涂层局部递送药物
|
US8182830B2
(en)
*
|
2010-01-05 |
2012-05-22 |
Medtronic Vascular, Inc. |
Hydrogen sulfide generating polymers
|
WO2011092564A2
(fr)
|
2010-01-28 |
2011-08-04 |
Fresenius Kabi Oncology Ltd |
Procédé amélioré pour la préparation du temsirolimus et de ses intermédiaires
|
US11369498B2
(en)
|
2010-02-02 |
2022-06-28 |
MT Acquisition Holdings LLC |
Stent and stent delivery system with improved deliverability
|
JP2013521002A
(ja)
|
2010-03-05 |
2013-06-10 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
誘導樹状細胞組成物及びその使用
|
EP2560576B1
(fr)
|
2010-04-22 |
2018-07-18 |
Micell Technologies, Inc. |
Endoprothèses et autres dispositifs ayant un revêtement de matrice extracellulaire
|
EP2563391B1
(fr)
|
2010-04-27 |
2020-08-26 |
Roche Glycart AG |
Polythérapie d'un anticorps CD20 afucosylaté avec un inhibiteur mTOR
|
WO2011151704A2
(fr)
|
2010-06-02 |
2011-12-08 |
Fresenius Kabi Oncology Ltd. |
Compositions pharmaceutiques stables d'esters de rapamycine
|
US20130172853A1
(en)
|
2010-07-16 |
2013-07-04 |
Micell Technologies, Inc. |
Drug delivery medical device
|
WO2012017449A1
(fr)
*
|
2010-08-04 |
2012-02-09 |
Meril Life Sciences Pvt. Ltd |
Procédé de préparation de nouveaux composés de 42-o-(hétéroalcoxyalkyl)rapamycine ayant des propriétés antiprolifératives
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012068487A1
(fr)
|
2010-11-18 |
2012-05-24 |
Synta Pharmaceuticals Corp. |
Présélection de patients pour un traitement thérapeutique fondé sur un état hypoxique, avec des agents sensibles à l'oxygène
|
CA2817564A1
(fr)
|
2010-11-18 |
2012-05-24 |
Ronald K. Blackman |
Preselection de patients pour un traitement therapeutique fonde sur un etat hypoxique
|
ES2423798T3
(es)
|
2010-11-19 |
2013-09-24 |
Universitätsklinikum Freiburg |
Hidrogeles de PEG disolubles sensibles a estímulos biofuncionalizados
|
CN102020662B
(zh)
*
|
2011-01-07 |
2013-02-13 |
天津市炜杰科技有限公司 |
一种驮瑞塞尔制备方法
|
EP2675451B9
(fr)
|
2011-02-18 |
2017-07-26 |
Novartis Pharma AG |
Plurithérapie impliquant un inhibiteur de mtor et un inhibiteur de jak
|
US9051336B2
(en)
|
2011-04-01 |
2015-06-09 |
Sandoz |
Regioselective acylation of rapamycin at the C-42 position
|
AU2012245971A1
(en)
|
2011-04-21 |
2013-10-17 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2012149014A1
(fr)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
|
JP2014516075A
(ja)
|
2011-06-06 |
2014-07-07 |
シェブロン フィリップス ケミカル カンパニー エルピー |
癌治療のためのメタロセン化合物の使用
|
EP2532740A1
(fr)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
|
CA2841360A1
(fr)
|
2011-07-15 |
2013-01-24 |
Micell Technologies, Inc. |
Dispositif medical d'administration de medicament
|
WO2013013708A1
(fr)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Traitement du rejet aigu dans une transplantation rénale
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
CN102424829B
(zh)
*
|
2011-10-26 |
2013-10-16 |
苏州汉酶生物技术有限公司 |
一种酶催化合成坦西莫司的方法
|
US9642918B2
(en)
|
2011-12-16 |
2017-05-09 |
Pfizer Inc. |
Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
|
GB201122305D0
(en)
|
2011-12-23 |
2012-02-01 |
Biotica Tech Ltd |
Novel compound
|
WO2013126797A1
(fr)
|
2012-02-24 |
2013-08-29 |
Purdue Research Foundation |
Ciblage du récepteur de la cholécystokinine de type b pour imagerie et thérapie
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
CN102796115B
(zh)
*
|
2012-05-25 |
2015-07-15 |
上海现代制药股份有限公司 |
一种坦西莫司的制备方法
|
CN103705925B
(zh)
|
2012-09-29 |
2018-03-30 |
段磊 |
抑制PI3K/AKT/mTOR信号通路的药物组合
|
US9750728B2
(en)
|
2012-09-29 |
2017-09-05 |
Targeted Therapeutics, Llc |
Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
|
WO2014059295A1
(fr)
|
2012-10-12 |
2014-04-17 |
The Board Of Regents Of The University Of Texas System |
Utilisation d'inhibiteurs mtor pour traiter le déficit cognitif vasculaire
|
KR20150070318A
(ko)
|
2012-10-16 |
2015-06-24 |
엔도사이트, 인코포레이티드 |
비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법
|
US20150258127A1
(en)
|
2012-10-31 |
2015-09-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
CA2897826C
(fr)
|
2013-01-09 |
2022-09-27 |
Taylor H. Schreiber |
Compositions et procedes pour la regulation de lymphocytes t regulateurs a l'aide d'une proteine d'une fusion tl1a-ig
|
CN110423282B
(zh)
|
2013-02-15 |
2023-09-08 |
加利福尼亚大学董事会 |
嵌合抗原受体及其使用方法
|
JP6330024B2
(ja)
|
2013-03-12 |
2018-05-23 |
マイセル・テクノロジーズ,インコーポレイテッド |
生体吸収性バイオメディカルインプラント
|
EP2968281B1
(fr)
|
2013-03-13 |
2020-08-05 |
The Board of Regents of The University of Texas System |
Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux
|
KR20150127720A
(ko)
|
2013-03-14 |
2015-11-17 |
유니버시티 오브 매릴랜드, 발티모어 |
안드로겐 수용체 하향 조절제 및 그의 용도
|
WO2014182635A1
(fr)
|
2013-05-08 |
2014-11-13 |
Baldwin Megan E |
Marqueurs biologiques de la dégénérescence maculaire liée à l'âge (dmla)
|
WO2014186532A1
(fr)
|
2013-05-15 |
2014-11-20 |
Micell Technologies, Inc. |
Implants biomedicaux bioabsorbables
|
CN103421023B
(zh)
*
|
2013-07-30 |
2015-09-23 |
福建省微生物研究所 |
一种替西罗莫司的合成工艺
|
BR112016002970A2
(pt)
|
2013-08-12 |
2017-09-12 |
Tokai Pharmaceuticals Inc |
biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
|
WO2015073644A1
(fr)
|
2013-11-13 |
2015-05-21 |
Novartis Ag |
Inhibiteurs de mtor ameliorant la reponse immunitaire
|
EP2878312A1
(fr)
|
2013-12-02 |
2015-06-03 |
Albert-Ludwigs-Universität Freiburg |
Nanosupports de PEGylation réversible
|
CA2931684C
(fr)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Recepteurs antigeniques chimeriques de la mesotheline humaine et leurs utilisations
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
CA2933908C
(fr)
|
2013-12-31 |
2024-01-30 |
Rapamycin Holdings, Llc |
Preparations orales de nanoparticules de rapamycine, et utilisation
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
WO2015108912A1
(fr)
|
2014-01-16 |
2015-07-23 |
MUSC Foundation for Research and Development |
Nanosupports ciblés pour l'administration d'agents immunosuppresseurs
|
WO2015142661A1
(fr)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Récepteur d'antigène chimèrique régulable
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
CA2943609A1
(fr)
|
2014-03-27 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Conjugues de medicaments actives metaboliquement pour vaincre la resistance dans une therapie du cancer
|
KR102487608B1
(ko)
|
2014-04-07 |
2023-01-12 |
노파르티스 아게 |
항-cd19 키메라 항원 수용체를 사용한 암의 치료
|
CN106659758A
(zh)
|
2014-06-02 |
2017-05-10 |
儿童医疗中心有限公司 |
用于免疫调节的组合物和方法
|
CN112481283A
(zh)
|
2014-07-21 |
2021-03-12 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
WO2016014530A1
(fr)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
CN104086564B
(zh)
*
|
2014-07-30 |
2019-02-05 |
江苏奥赛康药业股份有限公司 |
一种高纯度坦罗莫司的制备方法
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
JP7084138B2
(ja)
|
2014-08-19 |
2022-06-14 |
ノバルティス アーゲー |
癌処置に使用するための抗cd123キメラ抗原受容体(car)
|
WO2016040806A1
(fr)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
Inhibiteurs de mtorc1
|
CN114621969A
(zh)
|
2014-09-17 |
2022-06-14 |
诺华股份有限公司 |
用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
|
EP2997977A1
(fr)
|
2014-09-19 |
2016-03-23 |
Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe |
Inhibiteurs de MTOR spécifiques dans le traitement d'une adrénoleucodystrophie à liaison X
|
AU2015330898B2
(en)
|
2014-10-08 |
2022-03-10 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
US10377818B2
(en)
|
2015-01-30 |
2019-08-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of treating glioma
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
EP4234685A3
(fr)
|
2015-04-17 |
2023-09-06 |
Novartis AG |
Procédés pour améliorer l'efficacité et l'expansion de cellules exprimant un récepteur antigénique chimérique
|
EP3286211A1
(fr)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
|
JP6857141B2
(ja)
|
2015-05-20 |
2021-04-14 |
ノバルティス アーゲー |
エベロリムスとダクトリシブとの薬学的組合せ
|
WO2016196655A1
(fr)
|
2015-06-03 |
2016-12-08 |
The Regents Of The University Of California |
Variants de cas9 et procédés d'utilisation associés
|
WO2017029391A1
(fr)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nouvelle méthode de traitement du cancer
|
AU2016352806A1
(en)
|
2015-11-11 |
2018-05-10 |
Novartis Ag |
Uses of myostatin antagonists, combinations containing them and uses thereof
|
US10765665B2
(en)
|
2015-11-24 |
2020-09-08 |
Melin Jeffrey |
Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
|
WO2020047527A2
(fr)
|
2018-09-02 |
2020-03-05 |
F1 Bioventures, Llc |
Procédés et compositions pour modifier génétiquement des lymphocytes dans le sang ou dans des pbmc enrichies
|
CA3031542A1
(fr)
|
2016-07-20 |
2018-01-25 |
University Of Utah Research Foundation |
Lymphocytes car-t cd229 et leurs procedes d'utilisation
|
CN109996549A
(zh)
|
2016-09-22 |
2019-07-09 |
墨卡托医疗系统公司 |
使用坦罗莫司治疗再狭窄
|
AR110676A1
(es)
|
2016-10-07 |
2019-04-24 |
Novartis Ag |
Tratamiento del cáncer utilizando receptores de antígenos quiméricos
|
CN110114070A
(zh)
|
2016-11-23 |
2019-08-09 |
诺华公司 |
使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
|
CN110603038A
(zh)
|
2017-02-10 |
2019-12-20 |
塔姆山治疗公司 |
雷帕霉素类似物
|
CA3054064A1
(fr)
|
2017-03-03 |
2018-09-07 |
F1 Oncology, Inc. |
Procedes et compositions pour la transduction et l'expansion de lymphocytes et la regulation de l'activite de ces derniers
|
EP3615055A1
(fr)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
|
WO2018213352A1
(fr)
|
2017-05-15 |
2018-11-22 |
C.R. Bard, Inc. |
Dispositif médical à revêtement d'élution de médicament et à couche intermédiaire
|
CN108948045A
(zh)
*
|
2017-05-20 |
2018-12-07 |
鲁南制药集团股份有限公司 |
一种替西罗莫司的制备方法
|
WO2018218182A1
(fr)
|
2017-05-26 |
2018-11-29 |
Mercator Medsystems, Inc. |
Polythérapie pour le traitement de la resténose
|
WO2019002168A1
(fr)
|
2017-06-26 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes et compositions pharmaceutiques de traitement du syndrome d'olmsted
|
US20210147801A1
(en)
|
2017-07-13 |
2021-05-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregs
|
AR112834A1
(es)
|
2017-09-26 |
2019-12-18 |
Novartis Ag |
Derivados de rapamicina
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
CN110382019B
(zh)
|
2018-03-14 |
2020-08-25 |
墨卡托医疗系统公司 |
用于局部药物递送的医疗器械和医疗方法
|
EP3784351A1
(fr)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Thérapies reposant sur des cellules car-t présentant une efficacité améliorée
|
AU2019262979B2
(en)
|
2018-05-01 |
2023-07-06 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mTOR inhibitors
|
WO2019213282A1
(fr)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarqueurs pour évaluer des cellules car-t pour prédire un résultat clinique
|
CA3098692A1
(fr)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
Analogues de rapamycine lies a c40, c28 et c32 en tant qu'inhibiteurs de mtor
|
CN112638436A
(zh)
|
2018-05-22 |
2021-04-09 |
界面生物公司 |
用于将药物递送至血管壁的组合物和方法
|
EP3826649A4
(fr)
|
2018-07-23 |
2022-07-20 |
Enclear Therapies, Inc. |
Méthodes de traitement de troubles neurologiques
|
WO2020023418A1
(fr)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Méthodes de traitement de troubles neurologiques
|
WO2020053125A1
(fr)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Procédés de traitement de la neurofibromatose
|
JP2022512594A
(ja)
|
2018-10-05 |
2022-02-07 |
ザンクト アンナ キンダークレプスフォルシュング |
キメラ抗原受容体(car)の群
|
EP3632461A1
(fr)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
Groupe de récepteurs d'antigène chimérique (cars)
|
EP3632460A1
(fr)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
Groupe de récepteurs d'antigènes chimériques (cars)
|
JP2022504191A
(ja)
|
2018-10-05 |
2022-01-13 |
ザンクト アンナ キンダークレプスフォルシュング |
キメラ抗原受容体(car)群
|
WO2020101675A1
(fr)
|
2018-11-14 |
2020-05-22 |
Lutonix, Inc. |
Dispositif médical avec revêtement à élution de médicament sur un dispositif à surface modifiée
|
SG11202106635WA
(en)
|
2018-12-21 |
2021-07-29 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate and kinase inhibitor
|
CN113939324A
(zh)
|
2019-04-08 |
2022-01-14 |
巴德外周血管股份有限公司 |
在经改性装置表面上具有药物洗脱涂层的医疗装置
|
KR20220011123A
(ko)
|
2019-04-11 |
2022-01-27 |
엔클리어 테라피스, 인크. |
뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
|
CN113372359A
(zh)
*
|
2020-03-10 |
2021-09-10 |
鲁南制药集团股份有限公司 |
一种坦西莫司的制备方法
|
JP2023550544A
(ja)
|
2020-11-03 |
2023-12-01 |
アールディスカバリー エルエルシー |
がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法
|
CA3223081A1
(fr)
|
2021-07-15 |
2023-01-19 |
Samir Mitragotri |
Compositions et methodes associees a des cellules comprenant des particules adherees
|
WO2024008799A1
(fr)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Méthodes de traitement de la glomérulonéphrite proliférative
|
WO2024028433A1
(fr)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Procédés de traitement de troubles lymphoprolifératifs
|
WO2024100236A1
(fr)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Polythérapies pour le traitement du cancer
|